Publisher： John Wiley & Sons Inc
E-ISSN： 1538-7836|13|11|2041-2052
ISSN： 1538-7933
Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.11, 2015-11, pp. : 2041-2052
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
SummaryBackgroundConventional coagulation factor assays are associated with certain limitations, as they do not always reflect the clinical heterogeneity of bleeding in hemophilic patients or correctly reflect the individual patient response to treatment with bypassing agents or novel factor concentrates. The thrombin generation assay (TGA) is currently being assessed as a possible method for characterizing bleeding phenotypes in individuals with hemophilia.ObjectivesThis study assessed the robustness and sensitivity of the TGA for measuring the activity of recombinant factor VIII (rFVIII), recombinant factor IX (rFIX) and their glycoPEGylated derivatives, N8‐GP and N9‐GP, in vitro.MethodsFactor‐deficient plasma was spiked with 0.13–130 IU dL−1rFVIII or N8‐GP (hemophilia A [HA] plasma), or rFIX or N9‐GP (hemophilia B [HB] plasma). A calibrated automated thrombogram triggered with tissue factor (TF) or activated FXI (FXIa) was used to measure thrombin generation over time. Endogenous thrombin potential, peak thrombin, velocity index, lag time and time to peak thrombin were analyzed.ResultsFXIa‐triggered assays were not affected by glycoPEGylation and were sufficiently sensitive to differentiate between spiked samples mimicking severe and moderate HB and HA; TF‐triggered assays were not sufficiently sensitive for this distinction in HA. Both FXIa‐triggered and TF‐triggered assays had an acceptable level of variability (≤ 20%), although TF‐triggered assays were associated with greater variability.ConclusionsFXIa‐triggered TGA reactions produced more robust and sensitive results than TF‐triggered TGA reactions, and have the potential for use in monitoring patients treated with glycoPEGylated or non‐PEGylated coagulation factor concentrates. These promising results merit confirmation with clinical samples to correlate in vitro and in vivo data.
Related content
Access to resources
Recommend
